Generation Bio Co. (NASDAQ:GBIO – Get Free Report) saw a large decrease in short interest in September. As of September 30th, there was short interest totalling 2,010,000 shares, a decrease of 6.1% from the September 15th total of 2,140,000 shares. Based on an average trading volume of 104,700 shares, the days-to-cover ratio is presently 19.2 days. Currently, 4.1% of the shares of the company are short sold.
Wall Street Analysts Forecast Growth
GBIO has been the topic of a number of analyst reports. Wedbush restated an “outperform” rating and set a $5.00 target price on shares of Generation Bio in a research note on Thursday, August 8th. Needham & Company LLC reiterated a “buy” rating and set a $10.00 target price on shares of Generation Bio in a research report on Thursday, August 8th. Three investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $7.50.
Check Out Our Latest Stock Report on Generation Bio
Institutional Trading of Generation Bio
Generation Bio Stock Up 1.7 %
NASDAQ GBIO traded up $0.04 on Wednesday, reaching $2.46. The company had a trading volume of 112,779 shares, compared to its average volume of 186,276. The stock has a market capitalization of $163.66 million, a PE ratio of -0.96 and a beta of 2.80. Generation Bio has a 12 month low of $0.86 and a 12 month high of $4.65. The firm’s 50 day moving average price is $2.50 and its 200 day moving average price is $2.89.
Generation Bio (NASDAQ:GBIO – Get Free Report) last issued its earnings results on Wednesday, August 7th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.27) by ($0.04). The firm had revenue of $4.09 million during the quarter, compared to the consensus estimate of $3.23 million. Generation Bio had a negative return on equity of 92.86% and a negative net margin of 1,202.56%. On average, research analysts expect that Generation Bio will post -1.8 EPS for the current year.
About Generation Bio
Generation Bio Co develops non-viral genetic medicines for the treatment of rare and prevalent diseases. The company develops cell-targeted lipid nanoparticle (ctLNP) platform, a modular delivery system for nucleic acids to avoid off-target clearance by the liver and spleen that enables ctLNPs to persist in systemic circulation, which allows for highly selective and potent ligand-driven targeting to specific tissues and cell types; and novel immune-quiet DNA (iqDNA) to enable long-lasting high levels of gene expression from non-integrating episomes and avoids innate immune sensors that have long prevented DNA from use in non-viral systems.
See Also
- Five stocks we like better than Generation Bio
- What is the S&P/TSX Index?
- Taiwan Semiconductor Stock: Buy Now or Wait for Earnings?
- Where Do I Find 52-Week Highs and Lows?
- Abbott’s Growth and Dividends Make It a Smart Portfolio Pick
- Stock Sentiment Analysis: How it Works
- Citigroup Faces Growing Troubles: Could the Industry Be at Risk?
Receive News & Ratings for Generation Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Generation Bio and related companies with MarketBeat.com's FREE daily email newsletter.